Top Page
Tivic Health Systems
(NASDAQ:TIVC)
Tivic Health Systems (TIVC) vs. SPDR S&P 500 ETF (SPY)
Tivic Health Systems Business Overview & Revenue Model
Tivic Health Systems Earnings Call Summary
Tivic Health Systems Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 780.00K | 1.18M | 1.84M | 1.17M | 860.00K |
| Gross Profit | 2.00K | 287.00K | 299.00K | -129.00K | -225.00K |
| EBITDA | -5.31M | -8.06M | -9.92M | -6.65M | -3.21M |
| Net Income | -5.66M | -8.24M | -10.10M | -8.49M | -4.08M |
Balance Sheet | |||||
| Total Assets | 2.81M | 5.16M | 5.86M | 15.04M | 1.53M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 3.40M | 3.52M | 12.97M | 1.04M |
| Total Debt | 0.00 | 369.00K | 530.00K | 708.00K | 1.47M |
| Total Liabilities | 272.00K | 1.58M | 2.23M | 1.76M | 2.71M |
| Stockholders Equity | 2.54M | 3.58M | 3.63M | 13.27M | -1.18M |
Cash Flow | |||||
| Free Cash Flow | -5.72M | -8.63M | -8.93M | -5.61M | -3.03M |
| Operating Cash Flow | -5.72M | -8.51M | -8.92M | -5.61M | -3.03M |
| Investing Cash Flow | 0.00 | -118.00K | -11.00K | 0.00 | 0.00 |
| Financing Cash Flow | 4.33M | 8.51M | -528.00K | 17.54M | 1.76M |
Tivic Health Systems Technical Analysis
Tivic Health Systems Risk Analysis
Tivic Health Systems Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
46 Neutral | C$198.38M | -2.33 | -23.14% | 2.83% | 20.73% | -1.08% | |
45 Neutral | $4.67M | ― | -800.00% | ― | -35.03% | 57.39% | |
43 Neutral | $3.59M | ― | -218.77% | ― | -33.67% | 91.72% | |
41 Neutral | $1.96M | ― | -136.26% | ― | 9.57% | 10.03% | |
38 Underperform | $1.69M | ― | -679.99% | ― | 55.17% | 40.47% | |
29 Underperform | $2.36M | ― | -200.56% | ― | ― | 81.35% |
Tivic Health Systems Corporate Events
On April 10, 2025, Tivic Health Systems announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a series of events where the company faced potential delisting due to its stock price falling below $1.00 for 33 consecutive days in 2024. After implementing a reverse stock split and meeting the necessary requirements, Nasdaq confirmed compliance, allowing Tivic Health to maintain its market position and providing stability for its stakeholders.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
Tivic Health Systems’ stock faces challenges primarily due to weak financial performance characterized by declining revenues and consistent losses. Despite strategic transformations and potential growth in pharmaceuticals, the current financial health and bearish technical indicators significantly impact the stock’s attractiveness. The company’s efforts to diversify and strategic acquisitions offer future potential but are currently overshadowed by the need for improved operational efficiency and profitability.
To see Spark’s full report on TIVC stock, click here.
On March 18, 2025, Tivic Health Systems entered into an Equity Purchase Agreement with Mast Hill Fund, allowing Tivic to sell up to $25 million in common stock over 24 months. This agreement provides Tivic with financial flexibility to support its strategic initiatives, including expanding its biopharmaceutical program and advancing its non-invasive cervical vagus nerve stimulation devices. The company also reported a 30% reduction in net loss for 2024, reflecting improved financial management. Tivic’s recent strategic moves, including acquiring rights to Entolimod™ and appointing new leadership, aim to enhance its market position and drive growth in the biotech sector.
Tivic Health Systems, Inc. announced a 1-for-17 reverse stock split of its common stock, effective March 7, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. The reverse split is part of the company’s compliance plan to maintain its Nasdaq listing, following a notification from Nasdaq about non-compliance due to the stock’s low trading price. The reverse split will adjust the number of shares and conversion prices, but will not affect the overall ownership percentage of stockholders, aiming to increase the stock price above the $1.00 requirement.
On February 18, 2025, Tivic Health Systems announced the appointment of Michael Handley as Chief Operating Officer and President of its Tivic Biopharma division. Handley, a seasoned professional with extensive experience in drug and device commercialization, will lead Tivic’s efforts to advance its newly licensed product, Entolimod, through regulatory approval and commercialization. This strategic move aims to expand Tivic’s biopharmaceutical capabilities and enhance its therapeutics pipeline, potentially increasing shareholder value.
On February 11, 2025, Tivic Health Systems entered into an exclusive licensing agreement with Statera Biopharma to acquire rights to the TLR5 agonist program, including Entolimod for treating Acute Radiation Syndrome (ARS), and options for additional indications. This agreement positions Tivic as a diversified therapeutics company with a broadened clinical pipeline, potentially leading to FDA approval for ARS treatment within 24 months. Tivic’s acquisition aligns with its strategic transformation towards tackling immune and autonomic dysregulation. The deal involves milestone and royalty payments and allows Tivic to expand its product offerings, potentially benefiting shareholders by managing investments strategically.